Nasdaq Stockholm AB: The observation status for OncoZenge AB is updated (465/23)

On August 3, 2023, the shares in OncoZenge AB (the "Company") were given
observation status with reference to the Company's decision to pause the
development of BupiZenge and the intention to seek a company within the life
science sector to make a reverse take-over or to merge with. The Company has
further stated that if a reverse take-over or a merger is not deemed possible,
or if sufficient financing is not secured, the alternative is to liquidate the
Company. 

On August 23, 2023, the shares in the Company were also given observation
status on the grounds that the Company's board of directors consisted of only
one board member. 

On September 8, 2023, the Company issued a press release with information that
two new members had been elected to the Company's board of directors, thereby
consisting of three board members. 

With reference to the above, Nasdaq Stockholm AB decides to update the grounds
for the observation status for the shares in OncoZenge AB (ONCOZ, ISIN code
SE0015504097, order book ID 216185). 

For further information about this exchange notice please contact Enforcement &
Investigations, telephone [phone].